A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine in Pneumococcal Infections, sponsored by Pfizer. Completed at 8 sites in Japan. Open to participants aged 6 Years to 64 Years. Per ClinicalTrials.gov, last updated 2020-02-18.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 32nd largest by enrollment, is one of 6 that started in 2018, is one of 19 in phase 3, and was the 34th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 6 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 6 started in 2018.
This study's enrollment of 206 is below the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 48th largest by enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2018, is one of 33 in phase 3, and was the 44th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the safety, tolerability and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese subjects aged 6 to 64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13-valent pneumococcal conjugate vaccine
A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
Also known as: 13vPnC
Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years
Local reactions were recorded using an electronic daily diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.0 centimeter \[cm\]), moderate (greater than \[\>\] 2.0 to 7.0 cm) and severe (\>7.0 cm) for participants aged 6 to \<12 years, and as mild (2.5 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and, severe (\>10.0 cm) for participants aged 12 to \<18 years. Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
Time frame: Day 1 up to Day 7
Percentage of Participants Reporting Pre-Specified Local Reactions Within 14 Days After Vaccination in Participants Aged Between 18 to <65 Years
Local reactions were recorded using an electronic daily diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (2.5 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and, severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
Time frame: Day 1 up to Day 14
Percentage of Participants Reporting Systemic Events and Use of Antipyretic or Pain Medication Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years
Systemic events included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain, and were recorded by using an e-diary. Use of antipyretic or pain medication was also collected by using an e-diary. Fever was graded as 37.5 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (greater than or equals to \[\>=\] 6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (significant, prevented daily activity).
Time frame: Day 1 up to Day 7
Percentage of Participants Reporting Systemic Events and Use of Antipyretic or Pain Medication Within 14 Days After Vaccination in Participants Aged Between 18 to <65 Years
Systemic events included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain, and were recorded by using an e-diary. Use of antipyretic or pain medication was also collected by using an e-diary. Fever was graded as 37.5 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (significant, prevented daily activity).
Time frame: Day 1 up to Day 14
Percentage of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. An SAE is any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect.
Time frame: signing of informed consent form (Day 1) up to Day 43
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at Pre-vaccination and 1 Month After Vaccination
Antibody-mediated serum OPA against each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a quantitative functional microcolony OPA (mcOPA) assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). Two (2)-sided 95% CIs were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed based on the Student t distribution. OPA titer was expressed as reciprocal of highest serum dilution.
Time frame: Pre-vaccination and 1 month after vaccination
Geometric Mean Fold Rises (GMFRs) in Serotype-specific OPA Titers 1 Month After Vaccination
OPA GMFRs were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. GMFRs were computed as the fold rise in titer value at 1 month after vaccination compared to baseline (pre-vaccination). The CIs for GMFRs were back transformations of a CI based on the Student t distribution for the mean difference of the log-transformed assay results before vaccination and 1 month after vaccination.
Time frame: Pre-vaccination to 1 month after vaccination
Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at Pre-vaccination and 1 Month After Vaccination
Pneumococcal IgG antibody against each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using direct binding Luminex assay. Results were expressed as IgG concentrations. IgG concentrations were logarithmically transformed for analysis; geometric means calculated and expressed as GMCs. Two (2)-sided 95% CIs were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed based on the Student t distribution.
Time frame: Pre-vaccination and 1 month after vaccination
GMFRs in Serotype-specific IgG From Before Vaccination to 1 Month After Vaccination
IgG GMFRs were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. GMFRs were computed as the fold rise in concentrations at 1 month after vaccination compared to baseline (pre-vaccination). The CIs for GMFRs were back transformations of a CI based on the Student t distribution for the mean difference of the log-transformed assay results before vaccination and 1 month after vaccination.
Time frame: Pre- vaccination to 1 month after vaccination
| Milestone | 13vPnC: 6 to <18 Years | 13vPnC: 18 to <65 Years |
|---|---|---|
| Started | 53 | 153 |
| Vaccinated | 53 | 153 |
| Completed | 53 | 153 |
| Not completed | 0 | 0 |
Local reactions were recorded using an electronic daily diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.0 centimeter \[cm\]), moderate (greater than \[\>\] 2.0 to 7.0 cm) and severe (\>7.0 cm) for participants aged 6 to \<12 years, and as mild (2.5 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and, severe (\>10.0 cm) for participants aged 12 to \<18 years. Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
| percentage of participants | 13vPnC: 6 to <18 Years |
|---|---|
| Redness: Any | 21.3 (10.7 to 35.7) |
| Redness: Mild | 10.6 (3.5 to 23.1) |
| Redness: Moderate | 10.6 (3.5 to 23.1) |
| Redness: Severe | 0.0 (0.0 to 7.5) |
| Swelling: Any | 34.0 (20.9 to 49.3) |
| Swelling: Mild | 14.9 (6.2 to 28.3) |
| Swelling: Moderate | 17.0 (7.6 to 30.8) |
| Swelling: Severe | 2.1 (0.1 to 11.3) |
| Pain at the injection site: Any | 78.8 (65.3 to 88.9) |
| Pain at the injection site: Mild | 57.7 (43.2 to 71.3) |
| Pain at the injection site: Moderate | 21.2 (11.1 to 34.7) |
| Pain at the injection site: Severe | 0.0 (0.0 to 6.8) |
Local reactions were recorded using an electronic daily diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (2.5 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and, severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
| percentage of participants | 13vPnC: 18 to <65 Years |
|---|---|
| Redness: Any | 7.4 (3.6 to 13.2) |
| Redness: Mild | 5.2 (2.1 to 10.4) |
| Redness: Moderate | 2.2 (0.5 to 6.4) |
| Redness: Severe | 0.0 (0.0 to 2.7) |
| Swelling: Any | 12.5 (7.5 to 19.3) |
| Swelling: Mild | 5.1 (2.1 to 10.3) |
| Swelling: Moderate | 7.4 (3.6 to 13.1) |
| Swelling: Severe | 0.0 (0.0 to 2.7) |
| Pain at the injection site: Any | 66.2 (57.9 to 73.8) |
| Pain at the injection site: Mild | 53.8 (45.3 to 62.1) |
| Pain at the injection site: Moderate | 11.0 (6.4 to 17.3) |
| Pain at the injection site: Severe | 1.4 (0.2 to 4.9) |
Systemic events included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain, and were recorded by using an e-diary. Use of antipyretic or pain medication was also collected by using an e-diary. Fever was graded as 37.5 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (greater than or equals to \[\>=\] 6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (significant, prevented daily activity).
| percentage of participants | 13vPnC: 6 to <18 Years |
|---|---|
| Fever: 37.5 degree C to 38.4 degree C | 12.5 (4.7 to 25.2) |
| Fever: 38.5 degree C to 38.9 degree C | 2.1 (0.1 to 11.1) |
| Fever: 39.0 degree C to 40.0 degree C | 0.0 (0.0 to 7.4) |
| Fever: >40.0 degree C | 0.0 (0.0 to 7.4) |
| Fatigue: Any | 37.5 (24.0 to 52.6) |
| Fatigue: Mild | 25.0 (13.6 to 39.6) |
| Fatigue: Moderate | 10.4 (3.5 to 22.7) |
| Fatigue: Severe | 2.1 (0.1 to 11.1) |
| Headache: Any | 24.5 (13.3 to 38.9) |
| Headache: Mild | 16.3 (7.3 to 29.7) |
| Headache: Moderate | 6.1 (1.3 to 16.9) |
| Headache: Severe | 2.0 (0.1 to 10.9) |
| Vomiting: Any | 0.0 (0.0 to 7.5) |
| Vomiting: Mild | 0.0 (0.0 to 7.5) |
| Vomiting: Moderate | 0.0 (0.0 to 7.5) |
| Vomiting: Severe | 0.0 (0.0 to 7.5) |
| Diarrhea: Any | 8.3 (2.3 to 20.0) |
| Diarrhea: Mild | 8.3 (2.3 to 20.0) |
| Diarrhea: Moderate | 0.0 (0.0 to 7.4) |
| Diarrhea: Severe | 0.0 (0.0 to 7.4) |
| Muscle pain: Any | 30.6 (18.3 to 45.4) |
| Muscle pain: Mild | 26.5 (14.9 to 41.1) |
| Muscle pain: Moderate | 4.1 (0.5 to 14.0) |
| Muscle pain: Severe | 0.0 (0.0 to 7.3) |
| Joint pain: Any | 6.3 (1.3 to 17.2) |
| Joint pain: Mild | 4.2 (0.5 to 14.3) |
| Joint pain: Moderate | 2.1 (0.1 to 11.1) |
| Joint pain: Severe | 0.0 (0.0 to 7.4) |
| Use of antipyretic or pain medication | 6.4 (1.3 to 17.5) |
Systemic events included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain, and were recorded by using an e-diary. Use of antipyretic or pain medication was also collected by using an e-diary. Fever was graded as 37.5 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (significant, prevented daily activity).
| percentage of participants | 13vPnC: 18 to <65 Years |
|---|---|
| Fever: 37.5 degree C to 38.4 degree C | 6.0 (2.6 to 11.4) |
| Fever: 38.5 degree C to 38.9 degree C | 0.0 (0.0 to 2.7) |
| Fever: 39.0 degree C to 40.0 degree C | 0.0 (0.0 to 2.7) |
| Fever: >40.0 degree C | 0.0 (0.0 to 2.7) |
| Fatigue: Any | 33.1 (25.4 to 41.5) |
| Fatigue: Mild | 25.4 (18.4 to 33.3) |
| Fatigue: Moderate | 7.7 (3.9 to 13.4) |
| Fatigue: Severe | 0.0 (0.0 to 2.6) |
| Headache: Any | 23.4 (16.7 to 31.3) |
| Headache: Mild | 19.1 (13.0 to 26.6) |
| Headache: Moderate | 4.3 (1.6 to 9.0) |
| Headache: Severe | 0.0 (0.0 to 2.6) |
| Vomiting: Any | 1.5 (0.2 to 5.2) |
| Vomiting: Mild | 1.5 (0.2 to 5.2) |
| Vomiting: Moderate | 0.0 (0.0 to 2.7) |
| Vomiting: Severe | 0.0 (0.0 to 2.7) |
| Diarrhea: Any | 18.4 (12.4 to 25.8) |
| Diarrhea: Mild | 15.6 (10.0 to 22.7) |
| Diarrhea: Moderate | 2.1 (0.4 to 6.1) |
| Diarrhea: Severe | 0.7 (0.0 to 3.9) |
| Muscle pain: Any | 27.3 (20.1 to 35.5) |
| Muscle pain: Mild | 20.9 (14.4 to 28.6) |
| Muscle pain: Moderate | 5.8 (2.5 to 11.0) |
| Muscle pain: Severe | 0.7 (0.0 to 3.9) |
| Joint pain: Any | 13.8 (8.5 to 20.7) |
| Joint pain: Mild | 9.4 (5.1 to 15.6) |
| Joint pain: Moderate | 3.6 (1.2 to 8.3) |
| Joint pain: Severe | 0.7 (0.0 to 4.0) |
| Use of antipyretic or pain medication | 8.2 (4.2 to 14.2) |
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. An SAE is any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect.
| percentage of participants | 13vPnC: All Participants |
|---|---|
| AEs | 16 |
| SAEs | 0 |
Antibody-mediated serum OPA against each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a quantitative functional microcolony OPA (mcOPA) assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). Two (2)-sided 95% CIs were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed based on the Student t distribution. OPA titer was expressed as reciprocal of highest serum dilution.
| titers | 13vPnC: All Participants |
|---|---|
| Pre-vaccination; Serotype 1 | 10 (9.2 to 10.2) |
| 1 month after vaccination; Serotype 1 | 152 (119.2 to 193.8) |
| Pre-vaccination; Serotype 3 | 11 (9.8 to 13.1) |
| 1 month after vaccination; Serotype 3 | 63 (52.6 to 75.8) |
| Pre-vaccination; Serotype 4 | 18 (14.5 to 22.1) |
| 1 month after vaccination; Serotype 4 | 1257 (896.0 to 1763.8) |
| Pre-vaccination; Serotype 5 | 16 (15.3 to 17.5) |
| 1 month after vaccination; Serotype 5 | 185 (143.9 to 237.5) |
| Pre-vaccination; Serotype 6A | 57 (44.1 to 74.9) |
| 1 month after vaccination; Serotype 6A | 2487 (1811.7 to 3415.0) |
| Pre-vaccination; Serotype 6B | 72 (56.3 to 93.0) |
| 1 month after vaccination; Serotype 6B | 1845 (1405.9 to 2421.9) |
| Pre-vaccination; Serotype 7F | 167 (137.0 to 203.3) |
| 1 month after vaccination; Serotype 7F | 2107 (1752.6 to 2532.5) |
| Pre-vaccination; Serotype 9V | 204 (166.6 to 249.7) |
| 1 month after vaccination; Serotype 9V | 1425 (1134.4 to 1789.8) |
| Pre-vaccination; Serotype 14 | 129 (97.9 to 171.1) |
| 1 month after vaccination; Serotype 14 | 1919 (1518.8 to 2424.0) |
| Pre-vaccination; Serotype 18C | 61 (46.3 to 81.0) |
| 1 month after vaccination; Serotype 18C | 1829 (1390.8 to 2405.1) |
| Pre-vaccination; Serotype 19A | 38 (29.9 to 47.8) |
| 1 month after vaccination; Serotype 19A | 955 (745.6 to 1223.2) |
| Pre-vaccination; Serotype 19F | 42 (34.8 to 50.4) |
| 1 month after vaccination; Serotype 19F | 1126 (849.5 to 1493.4) |
| Pre-vaccination; Serotype 23F | 14 (11.1 to 17.2) |
| 1 month after vaccination; Serotype 23F | 713 (506.7 to 1001.9) |
OPA GMFRs were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. GMFRs were computed as the fold rise in titer value at 1 month after vaccination compared to baseline (pre-vaccination). The CIs for GMFRs were back transformations of a CI based on the Student t distribution for the mean difference of the log-transformed assay results before vaccination and 1 month after vaccination.
| fold rise | 13vPnC: All Participants |
|---|---|
| Serotype 1 | 15.6 (12.33 to 19.82) |
| Serotype 3 | 5.5 (4.59 to 6.54) |
| Serotype 4 | 61.7 (42.80 to 88.99) |
| Serotype 5 | 11.2 (8.69 to 14.34) |
| Serotype 6A | 34.7 (24.39 to 49.44) |
| Serotype 6B | 21.9 (15.71 to 30.51) |
| Serotype 7F | 12.1 (9.84 to 14.76) |
| Serotype 9V | 6.8 (5.36 to 8.62) |
| Serotype 14 | 13.2 (9.63 to 18.04) |
| Serotype 18C | 26.7 (19.39 to 36.86) |
| Serotype 19A | 24.9 (19.05 to 32.66) |
| Serotype 19F | 26.6 (19.89 to 35.63) |
| Serotype 23F | 50.4 (35.70 to 71.16) |
Pneumococcal IgG antibody against each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using direct binding Luminex assay. Results were expressed as IgG concentrations. IgG concentrations were logarithmically transformed for analysis; geometric means calculated and expressed as GMCs. Two (2)-sided 95% CIs were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed based on the Student t distribution.
| microgram per milliliter (mcg/mL) | 13vPnC: All Participants |
|---|---|
| Pre-vaccination; Serotype 1 | 0.132 (0.109 to 0.161) |
| 1 month after vaccination; Serotype 1 | 4.427 (3.423 to 5.726) |
| Pre-vaccination; Serotype 3 | 0.115 (0.094 to 0.141) |
| 1 month after vaccination; Serotype 3 | 0.531 (0.437 to 0.646) |
| Pre-vaccination; Serotype 4 | 0.055 (0.045 to 0.068) |
| 1 month after vaccination; Serotype 4 | 1.826 (1.387 to 2.404) |
| Pre-vaccination; Serotype 5 | 0.058 (0.046 to 0.075) |
| 1 month after vaccination; Serotype 5 | 2.779 (1.972 to 3.915) |
| Pre-vaccination; Serotype 6A | 0.173 (0.133 to 0.224) |
| 1 month after vaccination; Serotype 6A | 4.070 (2.915 to 5.684) |
| Pre-vaccination; Serotype 6B | 0.105 (0.080 to 0.138) |
| 1 month after vaccination; Serotype 6B | 2.354 (1.631 to 3.396) |
| Pre-vaccination; Serotype 7F | 0.117 (0.092 to 0.150) |
| 1 month after vaccination; Serotype 7F | 4.670 (3.629 to 6.010) |
| Pre-vaccination; Serotype 9V | 0.067 (0.054 to 0.082) |
| 1 month after vaccination; Serotype 9V | 1.483 (1.131 to 1.944) |
| Pre-vaccination; Serotype 14 | 0.335 (0.252 to 0.447) |
| 1 month after vaccination; Serotype 14 | 7.769 (5.844 to 10.328) |
| Pre-vaccination; Serotype 18C | 0.168 (0.131 to 0.216) |
| 1 month after vaccination; Serotype 18C | 5.187 (4.026 to 6.682) |
| Pre-vaccination; Serotype 19A | 0.496 (0.391 to 0.629) |
| 1 month after vaccination; Serotype 19A | 7.616 (5.786 to 10.026) |
| Pre-vaccination; Serotype 19F | 0.217 (0.171 to 0.275) |
| 1 month after vaccination; Serotype 19F | 4.315 (3.241 to 5.744) |
| Pre-vaccination; Serotype 23F | 0.181 (0.143 to 0.228) |
| 1 month after vaccination; Serotype 23F | 6.283 (4.524 to 8.727) |
IgG GMFRs were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. GMFRs were computed as the fold rise in concentrations at 1 month after vaccination compared to baseline (pre-vaccination). The CIs for GMFRs were back transformations of a CI based on the Student t distribution for the mean difference of the log-transformed assay results before vaccination and 1 month after vaccination.
| fold rise | 13vPnC: All Participants |
|---|---|
| Serotype 1 | 33.445 (26.374 to 42.413) |
| Serotype 3 | 4.605 (3.839 to 5.524) |
| Serotype 4 | 32.960 (25.331 to 42.886) |
| Serotype 5 | 47.565 (36.867 to 61.368) |
| Serotype 6A | 23.587 (18.010 to 30.890) |
| Serotype 6B | 22.421 (17.045 to 29.493) |
| Serotype 7F | 39.843 (31.473 to 50.438) |
| Serotype 9V | 22.232 (17.426 to 28.362) |
| Serotype 14 | 23.161 (17.179 to 31.227) |
| Serotype 18C | 30.833 (24.008 to 39.597) |
| Serotype 19A | 15.354 (12.116 to 19.459) |
| Serotype 19F | 19.892 (15.552 to 25.443) |
| Serotype 23F | 34.809 (26.436 to 45.833) |
Collected over signing of informed consent form (Day 1) up to Day 43. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC: 6 to <18 Years | 0/53 (0%) | 0/53 (0%) | 49/53 (92.5%) |
| 13vPnC: 18 to <65 Years | 0/153 (0%) | 0/153 (0%) | 121/153 (79.1%) |
| 13vPnC: All Participants | 0/206 (0%) | 0/206 (0%) | 170/206 (82.5%) |
| Event | 13vPnC: 6 to <18 Years | 13vPnC: 18 to <65 Years | 13vPnC: All Participants |
|---|---|---|---|
| Pain at the injection siteGeneral disorders | 41/52 | 96/145 | 137/197 |
| FatigueGeneral disorders | 18/48 | 47/142 | 65/190 |
| Injection site swellingGeneral disorders | 16/47 | 17/136 | 33/183 |
| MyalgiaMusculoskeletal and connective tissue disorders | 15/49 | 38/139 | 53/188 |
| HeadacheNervous system disorders | 12/49 | 33/141 | 45/190 |
| RednessGeneral disorders | 10/47 | 10/135 | 20/182 |
| DiarrhoeaGastrointestinal disorders | 4/48 | 26/141 | 30/189 |
| PyrexiaGeneral disorders | 7/48 | 8/134 | 15/182 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/48 | 19/138 | 22/186 |
| PharyngitisInfections and infestations | 3/53 | 2/153 | 5/206 |
Safety analysis set included all participants who received 1 dose of study vaccine.
| Age, Continuous(years) | 13vPnC: 6 to <18 Years | 13vPnC: 18 to <65 Years | Total |
|---|---|---|---|
| Mean | 12.7 ± 2.66 | 49.0 ± 10.12 | 39.6 ± 18.18 |
| Sex: Female, Male(Participants) | 13vPnC: 6 to <18 Years | 13vPnC: 18 to <65 Years | Total |
|---|---|---|---|
| Female | 22 | 77 | 99 |
| Male | 31 | 76 | 107 |
| Race/Ethnicity, Customized(participants) | 13vPnC: 6 to <18 Years | 13vPnC: 18 to <65 Years | Total |
|---|---|---|---|
| Asian | 53 | 153 | 206 |
| Non-Hispanic/non-Latino/not of Spanish origin | 53 | 153 | 206 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jul 2018 to primary completion in Nov 2018, 4 months.
Results were first posted in Dec 2019, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 4 months is below that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine